These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35261094)

  • 21. Altered structural and functional connectivity in Posterior Cortical Atrophy and Dementia with Lewy bodies.
    Singh NA; Goodrich AW; Graff-Radford J; Machulda MM; Sintini I; Carlos AF; Robinson CG; Reid RI; Lowe VJ; Jack CR; Petersen RC; Boeve BF; Josephs KA; Kantarci K; Whitwell JL
    Neuroimage; 2024 Apr; 290():120564. PubMed ID: 38442778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
    Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
    Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies.
    Nedelska Z; Ferman TJ; Boeve BF; Przybelski SA; Lesnick TG; Murray ME; Gunter JL; Senjem ML; Vemuri P; Smith GE; Geda YE; Graff-Radford J; Knopman DS; Petersen RC; Parisi JE; Dickson DW; Jack CR; Kantarci K
    Neurobiol Aging; 2015 Jan; 36(1):452-61. PubMed ID: 25128280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of hippocampal atrophy on the cognitive phenotype of dementia with Lewy bodies.
    Elder GJ; Mactier K; Colloby SJ; Watson R; Blamire AM; O'Brien JT; Taylor JP
    Int J Geriatr Psychiatry; 2017 Nov; 32(11):1182-1189. PubMed ID: 28425185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topography of cortical thinning in the Lewy body diseases.
    Ye R; Touroutoglou A; Brickhouse M; Katz S; Growdon JH; Johnson KA; Dickerson BC; Gomperts SN
    Neuroimage Clin; 2020; 26():102196. PubMed ID: 32059167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies.
    Beyer MK; Larsen JP; Aarsland D
    Neurology; 2007 Aug; 69(8):747-54. PubMed ID: 17709706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies.
    Mak E; Donaghy PC; McKiernan E; Firbank MJ; Lloyd J; Petrides GS; Thomas AJ; O'Brien JT
    Neurobiol Aging; 2019 Jan; 73():74-81. PubMed ID: 30339962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffusion imaging in dementia with Lewy bodies: Associations with amyloid burden, atrophy, vascular factors and clinical features.
    Donaghy PC; Firbank M; Petrides G; Lloyd J; Barnett N; Olsen K; Thomas AJ; O'Brien JT
    Parkinsonism Relat Disord; 2020 Sep; 78():109-115. PubMed ID: 32814228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of microglial activation with white matter changes in dementia with Lewy bodies.
    Nicastro N; Mak E; Williams GB; Surendranathan A; Bevan-Jones WR; Passamonti L; Vàzquez Rodrìguez P; Su L; Arnold R; Fryer TD; Hong YT; Aigbirhio FI; Rowe JB; O'Brien JT
    Neuroimage Clin; 2020; 25():102200. PubMed ID: 32032816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of
    La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies.
    Kasanuki K; Iseki E; Fujishiro H; Yamamoto R; Higashi S; Minegishi M; Togo T; Katsuse O; Uchikado H; Furukawa Y; Hino H; Kosaka K; Sato K; Arai H
    J Neurol Sci; 2012 Mar; 314(1-2):111-9. PubMed ID: 22041339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Free-Water Changes in Dementia with Lewy Bodies.
    Chiu SY; Chen R; Wang WE; Armstrong MJ; Boeve BF; Savica R; Ramanan V; Fields JA; Graff-Radford N; Ferman TJ; Kantarci K; Vaillancourt DE;
    Mov Disord; 2024 May; 39(5):836-846. PubMed ID: 38477399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies.
    Abdelnour C; Ferreira D; Oppedal K; Cavallin L; Bousiges O; Wahlund LO; Hort J; Nedelska Z; Padovani A; Pilotto A; Bonanni L; Kramberger MG; Boada M; Westman E; Pagonabarraga J; Kulisevsky J; Blanc F; Aarsland D
    Neuroimage Clin; 2020; 27():102333. PubMed ID: 32674011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Amyloid on Cognitive Performance in Parkinson's Disease and Dementia with Lewy Bodies.
    Baik K; Kim HR; Park M; Lee Y; Na HK; Sohn YH; Seong JK; Lee PH
    Mov Disord; 2023 Feb; 38(2):278-285. PubMed ID: 36527414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies.
    Tam CW; Burton EJ; McKeith IG; Burn DJ; O'Brien JT
    Neurology; 2005 Mar; 64(5):861-5. PubMed ID: 15753423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive cortical thinning and subcortical atrophy in dementia with Lewy bodies and Alzheimer's disease.
    Mak E; Su L; Williams GB; Watson R; Firbank MJ; Blamire AM; O'Brien JT
    Neurobiol Aging; 2015 Apr; 36(4):1743-1750. PubMed ID: 25649023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.